FITC

FITC 製品リスト

  • 属性

    Antibody (1)

  • 製品ライブラリ

    オンライン (1)

  • Rabbit (1)

  • タグ

    - (1)

  • マーカー

    Acridinium ester Labeled (1)

製品番号発現システム製品説明タンパク質の構造純度特性
FIC-S288
Rabbit
HEK293
Anti-FITC Antibody, Rabbit IgG-Acridinium ester (F11) (MALS verified)
総数量1
  • 1

FITCバックグランド

Chemiluminescence immunoassay (CLIA) is a much more effective measurement with the advantages of high sensitivity, uniformity and broad dynamic range. However, in traditional chemiluminescent immunoassay (CLIA),microplate was applied to immobilize antigen or antibody by physical absorption, which holds a negative effect on the perfor-mance of assay because of the low specific surface area of micro-plate. The use of micromagnetic particles (MMPs) have proven to be a support for addressing the shortage of traditional CLIA mentioned above The chemiluminescent immunoassay is a technique used for disease diagnosis, drug development, chemical reaction monitoring, and many other applications. The MMPs-based chemiluminescence immunoassays could improve the surface area for immobilization, capture efficiency and accuracy of the assay, thus obtaining higher sensitivity and shorter analysis time.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
ZanzalintinibXL-092Phase 3 ClinicalExelixis IncSolid tumours; Leiomyosarcoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular
詳細
SitravatinibMGCD-516; IND-155305; MGCD-0516; MG-91516; MG-516Phase 3 ClinicalBreast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Endometrial Neoplasms; Lung Neoplasms; Metastatic breast cancer; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Carcinoma, Squamous Cell; Hepatic Insufficiency; Ureteral Neoplasms; Solid tumours; Lung Diseases; Liposarcoma; Uveal melanoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Biliary Tract Neoplasms
詳細
MRX-2843UNC-2371; UNC-2025; MRX-2843Phase 2 ClinicalUniversity Of North Carolina At Chapel HillLeukemia; Solid tumours; Neoplasms; Pathologic Processes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lung Neoplasms; Leukemia, Myeloid, Acute; Neoplastic Processes; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung
詳細
Merestinib5OGS5K699E; LY-2801653Phase 2 ClinicalEli Lilly And CompanyBiliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung
詳細
AdrixetinibQ-702Phase 2 ClinicalVichem Chemie, Max Planck Institute of Biochemistry, Lead Discovery Center GmbHErdheim-Chester Disease; Uterine Cervical Neoplasms; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Carcinoma, Hepatocellular; Lymphoma; Lymphoma, T-Cell, Cutaneous; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Primary Myelofibrosis; Histiocytic Sarcoma; Lymphoma, T-Cell, Peripheral; Histiocytosis, Langerhans-Cell; Lymphoma, Follicular; Histiocytosis, Sinus; Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Esophageal Neoplasms; Leukemia, Lymphoid; Stomach Neoplasms; Solid tumours; Hematologic Neoplasms
詳細
INCB-081776INCB-81776; INCB-081776Phase 1 ClinicalIncyte CorpSolid tumours; Squamous Cell Carcinoma of Head and Neck
詳細
NPS-1034HOPE-777; KDDF-201111-02Neopharma Ltd
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
Cabozantinib S-malateXL-184; BMS-907351; RO7047650; RO-7047650ApprovedExelixis IncCometriq, CabometyxUnited StatesThyroid Neoplasms; Carcinoma, NeuroendocrineExelixis Inc2012-11-29Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Meningioma; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp
詳細
  • 製品リスト
  • 市販薬剤に関する情報
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8